Source ID | Cohort | Study duration (years) | Study centres | Study setting | Study period | Sample size | Mean age of sample (years, SD) | % of males | Outcome | Time points of measurement |
Ahmadi-Abhari, 201420 | EPIC-Norfolk | 13 | 1 | England | 1993–2011 | 8062 | 58.5* (9.2) | 45 | FEV1, FVC | 3 (0, 4, 13 years) |
Bartholomew, 199821 | Busselton Population Health Surveys | 6 | 1 | Australia | 1966–1981 | 1499 | 41.6 (16.1) | 29.7 | FEV1, FVC | 3 (0, 3, 6 years) |
Burchfiel, 199522 | Kuakini Honolulu Heart Program | 6 | 1 | USA | 1965–1975 | 1248 | 54.6† | 100 | FEV1 | 3 (0, 2, 6 years) |
Burrows, 198623 | Tucson Epidemiological study of obstructive Lung Disease (TESOLD) | 9.6 | 1 | USA | 1972–1983 | 466 | 48.3 (19.1) | 33.9 | FEV1 | Mean 5.2 |
Griffith, 200124 | Cardiovascular Health Study | 7 | 4 | USA | 1989–1997 | 5242 | 73.5/72.7 (5.5)/(5.2) | 42.4 | FEV1, FVC | 3 (0, 4, 7 years) |
Lange, 199825 | Copenhagen City Heart Study | 15 | 1 | Denmark | 1976–1994 | 4305 | 51.7‡ | 37 | FEV1 | 3—Cycle 1: 1976–1978, Cycle 2: 1981–1983, Cycle 3: 1991–1994 |
Liao, 201526 | Framingham Heart Study | 17 | 1 | USA | 1983–2007 | 543 | 47.6* (10.5) | 38.1* | FEV1, FEV1/FVC | 5—Cycle 1: 1983–1987, Cycle 2: 1987–1991, Cycle 3: 1991–1995, Cycle 4: 1995–1998, Cycle 5: 2007 |
Luoto, 201835 | Good Aging in Skåne | 13.5 | 1 | Sweden | 2001–2014 | 387 | 70.6* (10.6) | 44.2* | FEV1, FVC | Aged <80: every 6 years Aged 80 or over: every 3 years |
Maselko, 200627 | MacArthur Successful Aging study | 7 | 3 | USA | 1988–1995 | 544 | 74 | 31.8 | PEFR | 3 (0, 3, 7 years) |
Pearson, 199828 | Baltimore Longitudinal Study of Aging | Males: 11.5 Females: 5.7 | 1 | USA | 1962–1991 | 173 | 42.4 | 52.6 | FEV1 | 4.6/3 (every 2 years) |
Pelkonen, 200129 | Seven Countries Study | 30 | 2 | Finland | 1959–1989 | 200 | 47.6 (30 years) 49.4 (15 years) | 100 | FEV0.75 | 6 (0, 5, 10, 15, 20, 25, 30 years) |
Proctor, 200630 | Origins of Variance in the Old-Old (OCTO-Twin) | 8 | 1 | Sweden | 1991–2003 | 579 | 83.2 (2.8) | 33.0 | PEFR | 5 (0, 2, 4, 6, 8 years) |
Sherman, 199231 | Six Cities study of Air Pollution and Health | 12 | 6 | USA | 1974–1989 | 1486 | 47.2/48.2* (12.3)/(12.5) | 32.0 | FEV1, FVC | 4 (0, 3, 6, 12 years) |
Triebner, 201732 | European Community Respiratory Health Survey | 19.7‡ | 8 | Denmark; Germany; Spain; France; Iceland; Norway; Sweden; Estonia | 1991–2012 | 648 | 36.2*‡ | 0 | FEV1, FVC | 3—Cycle 1: 1991–1994 Cycle 2: 1998–2002 Cycle 3: 2010–2012 |
Wang, 200433 | - | 5 | 1 | USA | 1985–1992 | 71 | 37‡* (19-65) | 100 | FEV1 | 3–11; every 6 months |
Xu, 199534 | Dutch Study on Asthma and Chronic Obstructive Pulmonary Diseases | 24 | 2 | The Netherlands | 1965–1990 | 6293 | 35.06/44.5 (10.5)/(11.4) | 22.5 | FEV1 | 9 (every 3 years) |
*Estimates include smokers.
†Calculated from taking the midpoint of each age group and averaging according to number of people in each age group.
‡Median (range).
# / # Indicates males/females.
FEV0.75, forced expiratory volume in 0.75 s; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PEFR, peak expiratory flow rate.